Review article · 2020 · Open access
Clinical significance of fluid biomarkers in Alzheimer’s Disease
Pharmacological Reports, 72(3), 528–542 · Published 8 May 2020 · DOI 10.1007/s43440-020-00107-0
In brief
“Clinical significance of fluid biomarkers in Alzheimer’s Disease” is a 2020 review article by Piotr Lewczuk and 3 co-authors, published in Pharmacological Reports. OpenAlex counts 57 citations as of 19 November 2026, which puts it in the top 3% of works published in 2020 by citations. It is open access under a CC BY licence: the full text is free to read at Pharmacological Reports.
- Citations
- 57
- Most cited in
- 2024 (13)
- Field-weighted impact
- 0.68
- References
- 165
- Authors
- 4
Abstract
The number of patients with Alzheimer's Disease (AD) and other types of dementia disorders has drastically increased over the last decades. AD is a complex progressive neurodegenerative disease affecting about 14 million patients in Europe and the United States. The hallmarks of this disease are neurotic plaques consist of the Amyloid-β peptide (Aβ) and neurofibrillary tangles (NFTs) formed of hyperphosphorylated Tau protein (pTau). Currently, four CSF biomarkers: Amyloid beta 42 (Aβ42), Aβ42/40 ratio, Tau protein, and Tau phosphorylated at threonine 181 (pTau181) have been indicated as core neurochemical AD biomarkers. However, the identification of additional fluid biomarkers, useful in the prognosis, risk stratification, and monitoring of drug response is sorely needed to better understand the complex heterogeneity of AD pathology as well as to improve diagnosis of patients with the disease. Several novel biomarkers have been extensively investigated, and their utility must be proved and eventually integrated into guidelines for use in clinical practice. This paper presents the research and development of CSF and blood biomarkers for AD as well as their potential clinical significance. Upper panel: Aβ peptides are released from transmembrane Amyloid Precursor Protein (APP) under physiological conditions (blue arrow). In AD, however, pathologic accumulation of Aβ monomers leads to their accumulation in plaques (red arrow). This is reflected in decreased concentration of Aβ1-42 and decreased Aβ42/40 concentration ratio in the CSF. Lower panel: Phosphorylated Tau molecules maintain axonal structures; hyperphosphorylation of Tau (red arrow) in AD leads to degeneration of axons, and release of pTau molecules, which then accumulate in neurofibrillary tangles. This process is reflected by increased concentrations of Tau and pTau in the CSF.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Lewczuk, P., Łukaszewicz‐Zając, M., Mroczko, P., & Kornhuber, J. (2020). Clinical significance of fluid biomarkers in Alzheimer’s Disease. Pharmacological Reports, 72(3), 528–542. https://doi.org/10.1007/s43440-020-00107-0
MLA 9
Lewczuk, Piotr, et al. “Clinical significance of fluid biomarkers in Alzheimer’s Disease.” Pharmacological Reports, vol. 72, no. 3, 2020, pp. 528–542. https://doi.org/10.1007/s43440-020-00107-0.
Chicago
Lewczuk, Piotr, Marta Łukaszewicz‐Zając, Piotr Mroczko, and Johannes Kornhuber. 2020. “Clinical significance of fluid biomarkers in Alzheimer’s Disease.” Pharmacological Reports 72 (3): 528–542. https://doi.org/10.1007/s43440-020-00107-0.
Harvard
Lewczuk, P. et al. (2020) ‘Clinical significance of fluid biomarkers in Alzheimer’s Disease’, Pharmacological Reports, 72(3), pp. 528–542. doi:10.1007/s43440-020-00107-0.
IEEE
P. Lewczuk, M. Łukaszewicz‐Zając, P. Mroczko, and J. Kornhuber, “Clinical significance of fluid biomarkers in Alzheimer’s Disease,” Pharmacological Reports, vol. 72, no. 3, pp. 528–542, 2020, doi: 10.1007/s43440-020-00107-0.
BibTeX
@article{lewczuk2020clinical,
title = {{Clinical significance of fluid biomarkers in Alzheimer’s Disease}},
author = {Lewczuk, Piotr and Łukaszewicz‐Zając, Marta and Mroczko, Piotr and Kornhuber, Johannes},
journal = {Pharmacological Reports},
year = {2020},
volume = {72},
number = {3},
pages = {528--542},
doi = {10.1007/s43440-020-00107-0},
url = {https://doi.org/10.1007/s43440-020-00107-0}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2020 | 5 | |
| 2021 | 7 | |
| 2022 | 7 | |
| 2023 | 5 | |
| 2024 | 13 | |
| 2025 | 12 | |
| 2026 | 8 |
Its field-weighted citation impact is 0.68: it has been cited 0.68 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Alzheimer's disease
- fluid biomarkers
- cerebrospinal fluid biomarkers
- blood biomarkers
- amyloid-beta
- tau protein
- p-tau181
- amyloid plaques
Work with this paper
Most-cited papers in Neuroscience
- The Rat Brain in Stereotaxic CoordinatesGeorge Paxinos, CHARLES R. R. WATSON · Elsevier eBooks · 1982 · 52,413 citations
- The assessment and analysis of handedness: The Edinburgh inventoryRichard Charles Oldfield · Neuropsychologia · 1971 · 36,725 citations
- EEGLAB: an open source toolbox for analysis of single-trial EEG dynamics including independent component analysisArnaud Delorme A, Scott Makeig · Journal of Neuroscience Methods · 2004 · 25,302 citations
- The Ecological Approach to Visual PerceptionMarc H. Bornstein, James J. Gibson · Journal of Aesthetics and Art Criticism · 1980 · 22,977 citations
- The Psychophysics ToolboxDavid H. Brainard · Spatial Vision · 1997 · 20,208 citations
Questions about this paper
How do I cite this paper in APA style?
Lewczuk, P., Łukaszewicz‐Zając, M., Mroczko, P., & Kornhuber, J. (2020). Clinical significance of fluid biomarkers in Alzheimer’s Disease. Pharmacological Reports, 72(3), 528–542. https://doi.org/10.1007/s43440-020-00107-0
How many times has this paper been cited?
57 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Pharmacological Reports: sign in and open the PDF from this page.
Who wrote this paper?
Piotr Lewczuk, Marta Łukaszewicz‐Zając, Piotr Mroczko, Johannes Kornhuber.
What is the DOI of this paper?
10.1007/s43440-020-00107-0, permanently at https://doi.org/10.1007/s43440-020-00107-0. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.